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In intrauterine growth restriction (IUGR), a subset of pregnancies undergoes placental vascular dysregulation resulting in restricted
blood flow and fetal hypoxemia. Altered transcription of hypoxic regulated plasminogen activator inhibitor 1 (PAI-1) has been
associated with pregnancy complications and angiogenic regulation. Here we assessed circulating PAI-1 as an indicator of placental
insufficiency. Venous umbilical PAI-1 of hypoxemic (VpO2 20 versus 35 mmHg, 𝑝 < 0.0001) placental insufficient pregnancies
(resistance index 0.9 versus 0.63, 𝑝 < 0.05) (𝑛 = 18) was compared to controls (𝑛 = 12). PAI-1 was increased (∼10-fold,
𝑝 < 0.001) and had a positive predictive ratio of 6.7. Further, PAI-1 levels correlated to blood oxygen (𝑟 = −0.68, 𝑝 < 0.0001).
The plasma’s angiogenic potency measured in vitro was associated with umbilical cord blood PAI-1 levels (𝑟 = 0.65, 𝑝 < 0.01).
This association was attenuated by PAI-1 inhibiting antibody (𝑝 < 0.001). The results demonstrate PAI-1 as a potential marker of
placental insufficiency and identify its close association with pathological hypoxia and angiogenesis in a subset of growth restricted
pregnancies.

1. Introduction
The pregnancy complication intrauterine growth restriction
(IUGR) occurring in 5–10% of pregnancies is a major contributor to our healthcare burden. Newborns with severe
IUGR (<1,500 g at term) have a 70-fold greater mortality
rate. Perhaps as critically, these IUGR infants are at much
greater risk for long term chronic disease including negative
cognitive and behavioral outcomes, as well as increased
risk of obesity and cardiovascular and metabolic disease
[1–5]. Biomarkers associated with the pathology could help
better predict those at risk of developing hypertension, heart
disease, and diabetes later in life.
In affluent societies the primary cause of IUGR is a
subset of patients that have deficient maternal fetal exchange
of gasses and nutrients stemming from a compromised
placental vasculature. Specifically, a reduction in vessel volume and degree of branching of the chorionic villous tree

increases the vascular resistance to blood flow of the fetalplacental circulation in the later stages of pregnancy [6]. This
condition termed placental insufficiency leads to slowed or
even arrested fetal umbilical artery diastolic flow compromising maternal/fetal exchange, causing fetal hypoxemia and
acidosis. The biochemical regulatory basis of angiogenesis
in placental insufficiency has therefore been of considerable
research interest in uncovering the pathological mechanisms.
As an inhibitor of urokinase-type and tissue-type plasminogen activators, plasminogen activator inhibitor-1 (PAI1) has long been implicated in thrombotic disease. PAI-1 is
the primary physiological inhibitor of plasminogen activation in blood, which either promotes or prevents vascular
remodeling processes; PAI-1 has been determined to be
a proangiogenic factor [7]. There is significant correlation
of circulating PAI-1 levels to tumor vascularization and
metastases [8–10]. Elevated plasma PAI-1 is a prognostic
biomarker for poor outcome in breast cancer [11–15]. It

2
functions through extracellular matrix (ECM) regulation,
which drives cell migration and angiogenesis [16].
In pregnancy PAI-1 is also secreted by the syncytiotrophoblast, where its increased mRNA levels have been histologically determined in preeclamptic placentas with IUGR
[17]. Its elevated maternal levels have previously been associated with clinical metrics of fetal blood supply [18]. PAI1 levels have been variably reported as decreased [19] or
unchanged [20] in IUGR pregnancies. Few studies have separated etiological differences of IUGR pregnancies, controlled
for conditions like preeclampsia, which though it has a large
overlap in diagnosis is likely an independent pathology [17,
20, 21], and have PAI-1 regulatory alterations of their own [22,
23]. Further, PAI-1 is downstream of numerous regulatory
pathways, including vascular endothelial growth factor A
(VEGF) and fibroblast growth factor 2 (FGF-2) that are both
implicated in the normal development of the placental vasculature [24, 25]. These cytokines in turn are themselves altered
in IUGR [26–29], presumably influencing PAI-1 expression.
Finally, the finding that, like VEGF, PAI-1 is downstream
of a hypoxic response element and therefore is regulated
via hypoxic inducible factor 1 (HIF-1) mediated induction
suggests a potential association between its expression and
the placental insufficiency pathology [30].
Levels of plasma PAI-1 in placental insufficiency are
therefore downstream of competing molecular regulatory
mechanisms related to hypoxia. Hypoxia is the main stimulus
for angiogenesis by signaling through hypoxia-inducible
transcription factors. Since fetal hypoxia is variable from
normal to life threatening in placental insufficiency, we
hypothesized that PAI-1 levels at birth could act as a marker
of placental insufficiency and further that the altered levels
would associate with the hypoxic and angiogenic changes
that underlay the pathology. From a restrictive subset of
very severe IUGR pregnancies that have a demonstrated
compromised vasculature and placental insufficiency as measured by umbilical Doppler, we set out to test if PAI-1 is
in fact changing in the fetal-placental plasma in placental
insufficiency, and also whether those changes are sufficient
to influence angiogenesis.

2. Materials and Methods
2.1. Subject Recruitment and Plasma Collection. Pregnant
women were recruited with informed consent from St.
Joseph’s Hospital, London, Canada, with approval by the University of Western Ontario Research Ethics Board. Women
with severe IUGR with placental insufficiency as diagnosed
by umbilical artery Doppler were included in the study (𝑛 =
18). Mothers with placental insufficiency were otherwise
healthy and absent for other significant pregnancy complications so as to minimize the biological variability associated
with diverse etiological factors underlying IUGR. Specific
exclusion criteria included multiple gestations, preeclampsia, placental abruption, fetal congenital abnormalities, fetal
or placental infection, and maternal diabetes, as well as
drug and alcohol use. Randomly selected gestational age
matched pregnancies were chosen that also excluded all
major obstetrical complications listed other than preterm
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birth. Because IUGR babies are at high risk for fetal morbidity
or mortality, these babies are frequently delivered preterm. In
order to gestational age-match the IUGR group, we selected
either preterm normal birth weight for gestational age or
term normal birth weight for gestational age babies, on a
balanced basis. These control pregnancies were otherwise free
of obstetrical complications (𝑛 = 12).
Women with suspected IUGR had estimated fetal weights
determined by fetal biometric ultrasound measurements,
with estimated fetal weight well below the tenth percentile
for GA to ensure selection of small for gestational age
infants that was confirmed to be below the 10th percentile
birth weight following delivery. Umbilical Doppler was
measured by a maximum of three days prior to delivery
to determine the placental resistance in IUGR pregnancies
and diagnose placental insufficiency. Since no IUGR was
suspected or diagnosed in most healthy term pregnancies,
Doppler measurements were not indicated within the last
week of pregnancy and therefore were not performed nor
abstracted for this study. All IUGR patients were confirmed
to be placental insufficient by umbilical Doppler (Table 1).
Gestational age was determined by last menstrual date of
mothers or the first trimester ultrasound crown rump length.
The groups were therefore separated by those with a low
birth weight given their gestational age, or percentile birth
weight (IUGR defined as <10th percentile), as the additional
subdiagnosis of placental insufficiency (Table 1).
Immediately following delivery the umbilical cord was
clamped and fetal blood extracted from the fetal umbilical
cord vein by venipuncture in EDTA coated tubes. One tube of
blood was analyzed at St. Joseph’s Hospital as part of normal
neonatal care, where blood gas values were immediately
determined by the clinical laboratory in hospital using a
Radiometer ABL 500 Blood Gas Analyzer. A second tube
from the same sampling was centrifuged at 3500 ×g for
15 min at 4∘ C, and the plasma supernatants were saved for
subsequent analysis at −80∘ C. Venous and arterial oxygen
levels were then determined from the same venipuncture as
the plasma samples collected immediately following delivery.
Oxygen values were abstracted from fetal charts.
The birth weight percentiles were calculated following
delivery using standardized growth charts [31]. A subset of
the IUGR pregnancies diagnosed with placental insufficiency
and confirmed growth restricted based on birthweight were
included. Though below the 10th percentile is indicative of
IUGR, of the 18 IUGR pregnancies included, all but 2 were
confirmed to be <3rd percentile, and all but 4 were below the
1st percentile. The low percentile likely reflects a combination
of selection of clear cases of IUGR and isolation of the severe
subtype of placental insufficiency as confirmed by umbilical
Doppler. The restrictive subset of low percentile IUGR
pregnancies with demonstrated compromised vasculature
ensured isolation of a clear etiological subset of IUGR babies.
All control pregnancies included were >25th percentile
for gestational age and gender. Pathological examination of
the placentas was undertaken at St. Joseph’s Hospital. Based
on review of the pathological reports and other information in the patient charts, some subjects were retroactively
excluded for diverse medical complications including fetal
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Table 1: Characteristics of IUGR patients with PI and gestational
age matched control pregnancies.

Subjects (𝑛)
Male
Female
Total:
Birth weight (g)
Gestational age (wk)
Birth weight percentile
Caesarean/vaginal
Maternal age (y)
Placental weight (g)
Placental resistance+
Maternal BP
Systolic
Diastolic
APGAR (5 min)

Control

PI

7
5
12
2172 (723)
33.1 (4.1)
51 (20)
6/6
27 (6)
502 (156)
0.63 (0.09)

13
5
18
1469∗ (637)
34.1 (3.8)
1.5∗∗∗ (3.0)
12/6
29 (6)
372∗ (151)
0.90∗ (0.23)

114 (10)
71 (8)
8.8 (0.4)

129∗ (16)
78 (12)
7.9 (2.3)

Comparison of means was by 𝑡-test or Mann-Whitney test following a
normality test (∗ 𝑝 < 0.05, ∗∗∗ 𝑝 < 0.001). Standard deviation is indicated
in brackets. Fetal blood samples were collected immediately following either
vaginal or Caesarean section delivery from the clamped umbilical cord vein
by venipuncture in EDTA coated tubes. Blood gas values were measured in
the clinical lab and values abstracted from fetal charts.
+
Placental resistance index from the last umbilical cord Doppler ultrasound
prior to delivery. All PI subjects were diagnosed with the vascular pathology
based on abnormally high resistance index for GA in the days preceding
delivery; the 5 of 12 controls that were tested are indicated.

congenital anomalies, major infarcts, or maternal antenatal
hypertension or suspected infection. The umbilical blood gas
levels used in this paper were also abstracted from the chart
for 16 of 18 IUGR and 12 of 12 controls. The blood samples
for protein analysis and for blood gas analysis were taken at
the same time and from the same venipuncture into separate
tubes. Due to the rarity of the cases based on restrictive
inclusion and exclusion criteria, both vaginal and Caesarean
section deliveries were included, and the effects of delivery
mode as well as gestational age were assessed.
2.2. HUVEC Culture and Angiogenic Assays. Human umbilical vein endothelial cells (HUVECs) (Lonza, Basel, Switzerland) were grown in Endothelial Growth Media (Lonza)
supplemented with 10% FBS, using CELL+ growth surface
coated flasks (Sarstedt, Numbrecht, Germany). For treatments, HUVECs were plated on ECMatrix (Millipore, MA,
USA) at a density of 1 × 104 or 3 × 104 cells per well
(96-well plate) with 50 𝜇L of FBS-free media. HUVECs
have played a major role as a model system for the study
of the regulation of the endothelium in the development
of atherosclerotic plaques and angiogenesis. In this study,
the plasma collected was added to Endothelial Base Media
(Lonza, Basel, Switzerland) (FBS-free) for a final concentration of 1% in 100 𝜇L of media to determine its effects of tubule
formation using HUVECs. The cells were allowed to grow
within ∼4–6 hours as per the in vitro Angiogenesis Assay
Kit protocol (Millipore, MA, USA). For PAI-1 neutralizing

antibody inhibitor treatments, mouse anti-PAI-1 antibodies
(BD Transduction Laboratories, Franklin, NJ, USA) were
added to the plasma in 30 𝜇L of base media and incubated
at RT for 1 hour. Cells were then added to the tubes, and
incubated for a further 10 minutes prior to plating. Three
bright field images were taken using an inverted microscope.
Leica FireCam software was used to capture the images (v3.4,
Leica Microsystems, Wetzlar, Germany). The tube length
was quantified using Axiovision software (v4.7.1, Carl Zeiss,
Germany), and branches were counted manually as per the
Angiogenesis Assay Kit and as described previously [32].
2.3. Protein Measurements and Statistical Evaluations. All
total protein quantifications were by Bradford method
(BioRad). FGF-2, VEGF, and PAI-1 were measured by an
immunological-based fluorescent multiplex assays (Human
CDV1, Millipore, Billerica, MA, USA) using a Bio-Plex
200 system (BioRad), which utilizes Luminex xMAPTM
fluorescent bead-based technology (Luminex Corp., Austin,
TX). Levels were automatically calculated from standard
curves using Bio-Plex Manager software (v4.1.1, BioRad). All
statistics were done using Prism 6 (Graph Pad Software Inc.,
CA, USA).
To compare means, 𝑡-tests for parametric or MannWhitney test for nonparametric data as appropriate was used
following an 𝐹 test. One-way ANOVAs were used to measure
significance across multiple means with Tukey’s post hoc test
to compare between means. Changing proteins’ levels were
compared to blood oxygen levels, as well as other quantitative
criteria abstracted from the clinical charts, and the degree
of angiogenesis measured in the angiogenic assay. Multicorrelational analysis was via Pearson’s correlation matrices. To
correct for multiple comparisons, a 𝑄 of 0.05 was calculated at
𝑝 < 0.01 which was considered the false discovery threshold
of correlational significance.
The receiver operating characteristic curve (ROC) was
determined by comparing the groups separated by the gold
standard of umbilical Doppler diagnosis of >95th percentile
of umbilical artery resistance index and confirmed growth
restriction as measured by percentile birth weight. The true
positive and false positive prediction rate were plotted and
compared against umbilical oxygen levels of the blood which
upregulate PAI-1 and are indicators of fetal hypoxemia and
morbidity but are unreliable as they are transient and rapidly
changing as a marker of placental insufficiency. The area
under the ROC was used to assess the accuracy of prediction,
where above 0.8 was considered good.

3. Results
Samples were collected from small for gestational age babies
that were first identified by routine ultrasound, lack of weight
gain, and other screening metrics, as likely IUGR possibly
caused by placental insufficiency. A subset of pregnancies
subsequently confirmed to be placental insufficient by umbilical artery Doppler were included. Because a large proportion
of these IUGR babies are delivered preterm to minimize
the risk of morbidity or mortality, they were gestational
age matched preterm or term controls as the appropriate
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GA matched control. Whether preterm or term, controls
were appropriate growth for their gestational age (∼50th
percentile birth weight) compared to small for gestational
age (∼3%) (Table 1). We therefore separated those with a
low birth weight given their gestational age as a result of
placental insufficiency, from those that had birth weight that
was appropriate for their gestational age (controls), regardless
of preterm or term birth (birth weight percentile, Table 1).
At birth, effluent placental blood samples were collected
from the umbilical cord vein. Mothers selected for the study,
spanned in gestational age from 26.5 to 39 weeks. Healthy
or often preterm controls were selected as gestational age
matched controls that were otherwise free of complications.
IUGR babies were confirmed to be growth restricted with
birth weight percentiles <10% for gestational age, and placentae weighing ∼125 g less on average (𝑝 < 0.05) (Table 1).
All pregnancies were diagnosed with placental insufficiency
based on umbilical artery Doppler. The resistance was
abnormally high for gestational age for all cases of IUGR,
demonstrating the vascular pathology of the study group,
while data was available for only 5 of 12 controls that were
all normal (Table 1). Although the maternal systolic blood
pressure was slightly elevated for the placental insufficiency
group, the overall normal blood pressure (BP) levels reflect
the exclusion of preeclampsia subjects.
The effluent placental blood collected from the umbilical
cord was analyzed for PAI-1 levels, and also for its cytokine
regulators VEGF and FGF-2, using a fluorescent multiplex
immunoassay. PAI-1 was dramatically elevated (∼10-fold, 𝑝 <
0.001) in placental insufficiency compared to control group
(Figure 1(a)). No corresponding change was detected for
total VEGF and FGF-2 (Figures 1(b) and 1(c)). The levels of
umbilical oxygen (abstracted from the fetal clinical chart),
however, were significantly reduced in placental insufficiency
(both venous and arterial, 𝑝 < 0.001 and 𝑝 < 0.05,
resp.) (Figures 1(d) and 1(e)), further indicating the restricted
exchange as a result of the placental vascular pathology.
Although venous cord blood oxygen levels were significantly different between control and placental insufficiency, there was no difference attributable to delivery
mode, in either control or placental insufficiency groups,
of either venous or arterial oxygen levels (Supplemental
Figure 1; see Supplementary Material available online at
http://dx.doi.org/10.1155/2016/7124186). Likewise the delivery
mode had no effect on the elevated levels of PAI-1, VEGF, and
FGF-2. PAI-1 and VEGF levels also did not change with gestational age; however FGF-2 decreased with gestational age
in controls only (Supplemental Figure 2), which is consistent
with expectations [33]. Similarly, as PAI-1 is upregulated by
corticosteroids in vitro we examined the effect of subjects
who received steroid treatments as prophylactic (<34 weeks)
compared with those who did not (>34 weeks). It was found
that the PAI-1 was increased in the <34-week group 42 ng/mL
versus 30 ng/mL; however this was not significant (𝑝 = 0.36).
This indicates that although there may be some effect, it
may be lost in the larger changes associated with placental
insufficiency.
Levels of VEGF or FGF-2, though unchanged between
placental insufficiency and control, correlated to the elevated
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concentrations of PAI-1 in control pregnancies (Figure 2(a)
(i) and (ii)). The relationships were strongly dependent,
where 𝑟 = 0.78 (𝑝 < 0.01) and 𝑟 = 0.89 (𝑝 < 0.001) for VEGF
and FGF-2, respectively. However, this dependency did not
carry over to the placental insufficiency group (Figure 2(b)
(i) and (ii)). Instead, for placental insufficiency pregnancies,
the higher concentration of PAI-1 in plasma was dependent
on the oxygen levels (𝑟 = −0.68, 𝑝 < 0.0001), where
there was no relationship in controls (Figure 2(a) (iii) versus
2(b) (iii)). ROC reveal PAI-1 to be approximately as sensitive
and as specific an indicator of placental insufficiency as
venous blood oxygen level following delivery (Figure 3).
The area under the curve was 0.847 for PAI-1 compared to
0.885 for venous cord blood oxygen. A cut-off value was
determined at >43.3 ng/mL, where PAI-1 has a sensitivity
of 55.6% and a specificity of 91.7% corresponding to a true
positive likelihood ratio of 6.7.
PAI-1 is considered to be a key molecule in thrombotic
vascular diseases that is upregulated in hypoxia. Given that
PAI-1 is an angiogenic mediator, we measured the effects of
the venous cord blood on angiogenesis, using an in vitro
HUVEC tube formation assay. HUVEC cells were plated on
extracellular matrix and were then subjected to 1% venous
umbilical cord plasma of placental insufficiency and control
pregnancies in a basal media. Representative images from the
assays are shown in Figure 4(a). The amount of angiogenic
potency of the placental insufficiency plasma relative to control was compared using total length of tube formation and
the number of branches per field as metrics using a standard
angiogenesis assay kit [34]. The placental insufficiency plasma
induced 1.5-fold greater tube length (𝑝 < 0.01) and a 2-fold
greater degree of tube branching (𝑝 < 0.001) compared to the
control group (Figure 4(b)).
When the degree of angiogenic induction by the plasma
was correlated against the proteins’ concentration, it was
revealed unsurprisingly that it correlated significantly to
total VEGF (but not FGF-2) levels in the plasma in both
measurements of tube formation and branching (𝑟 = 0.71,
and 𝑟 = 0.74, 𝑝 < 0.05, resp.) (Figure 5(a) (i)). However,
the correlation again did not carry over to the placental
insufficiency group (Figure 5(b) (i)). Instead, for placental
insufficiency pregnancies, the angiogenic potency correlated
to PAI-1 levels for both tube formation and branching (𝑟 =
0.65, 𝑝 < 0.01, and 𝑟 = 0.67, 𝑝 < 0.05, resp.), where there was
no relationship in controls (Figure 5(a) (ii) versus 5(b) (ii)).
To determine if the angiogenic changes observed were
directly related to PAI-1 levels, the umbilical cord plasma
from placental insufficiency pregnancies was subjected to
various concentrations of a PAI-1 activity neutralizing antibody. Representative fields from the tube formation assay
are shown in Figure 6(a). Quantifying the inhibition showed
the changes to be significant; 0.25 𝜇g/mL of antibody was
sufficient to suppress tube formation (𝑝 < 0.05), while
1.25 𝜇g/mL of anti-PAI-1 inhibited the total tube length and
the branches per field ∼2-fold (𝑝 < 0.001 and 𝑝 < 0.01,
resp.) (Figure 6(b)), which was similar to HUVECs grown
in the absence of plasma. The finding was reproducible
across six umbilical plasma samples tested (Figure 6(c)).
The inhibition of tube formation with neutralizing antibody
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Figure 1: Fetal umbilical cord plasma levels of PAI-1 are elevated in PI. Fetal umbilical cord plasma levels of PAI-1 and regulators of its
transcription were compared between PI. (a) PAI-1 is greatly increased in the fetal circulation in placental insufficiency (Mann-Whitney test,
∗∗∗ 𝑝
< 0.001). Total VEGF (b) and FGF-2 (c) levels were unchanged, while oxygen levels in both the venous (d) and arterial (e) umbilical
cord were decreased in placental insufficiency (𝑡-test, ∗ 𝑝 < 0.05, ∗∗∗ 𝑝 < 0.001). Blood gas measurements were performed in hospital by the
clinical laboratory for 16/18 PI and 11/12 control subjects as part of routine postnatal care. Multiplex immunofluorometric assays were used to
measure protein changes from the same samples. Box plots indicate median, interquartile range, and whiskers total range.

implicates umbilical cord plasma PAI-1 in the upregulated
angiogenesis of placental insufficiency.

4. Discussion
The findings of this study identify PAI-1 as a potential marker
of placental insufficiency and associate its levels directly with

not only the degree of hypoxia but also angiogenic regulation
changes that may underlay the pathology. Its predictive levels
were similar to that of routinely assessed hypoxia. Indeed
PAI-1 levels were in close step with the degree of hypoxia but
furthermore were also strongly associated with angiogenic
changes that may underlay the pathology. The fact that PAI1 levels and angiogenesis in turn are associated with hypoxia
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Figure 2: PAI-1 correlates to the expression of PAI-1 regulators in the fetal umbilical cord blood plasma. (a) In control pregnancies, PAI-1
levels are dependent on total VEGF (i) and FGF-2 (ii) levels (𝑟 = 0.78, 𝑝 < 0.01, and 𝑟 = 0.89, 𝑝 < 0.001, resp.), but not venous umbilical
oxygen (iii). (b) Conversely in PI pregnancies, PAI-1 expression has no relationship to total VEGF (i) or FGF-2 (ii) levels, but is instead
dependant on ambient oxygen levels (iii) (𝑟 = −0.68, 𝑝 < 0.0001) (open: control, closed: PI).

in placental insufficiency, and not its molecular angiogenic
regulators VEGF and FGF-2, indicates upregulation may
be largely through HIF-1 mediated mechanisms. Inhibiting
PAI-1 attenuated the plasma’s stimulation of tube formation
in a dose dependent manner, demonstrating PAI-1’s central
significance to angiogenesis as a circulating factor. Given the

known significant role of PAI-1 in angiogenesis, and its role
as a clinical biomarker of tumor vascularization, the extreme
upregulation (∼10-fold) of PAI-1 in the plasma may have
very significant consequences for vascular regulation in the
placenta. These data add to evidence of a key role of PAI-1
in the pathophysiology of IUGR. Further the results provide
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a basis for PAI-1 levels to be assessed for use as a marker of
placental disease following delivery for newborns determined
to be IUGR.
Blood gasses following delivery are typically used to assess
acidosis or alkalosis at delivery which may be acute. In this
study, patients were assessed as parentally insufficient and
the reduced umbilical oxygen levels and high carbon dioxide
observed are in most cases reflective of severely reduced
exchange in the placenta. The venous umbilical cord pO2 as
measured approximates that of placental oxygen, correlating
0.80 to the placental levels [35]. PAI-1 expression is known
to be upregulated by VEGF and FGF-2 [16]. The levels of
both of these cytokines in plasma correlated strongly with
PAI-1 levels (Figure 2(a) (i) and (ii)) (which in turn were
strongly related to angiogenic potency (Figure 5(a))), however, only for controls. In normal pregnancy the expression of
angiogenic cytokines may well be responsible for the largest
degree of PAI-1 expression and its corresponding influence
on angiogenesis.
It is surprising that VEGF did not increase in hypoxic
conditions of placental insufficiency, nor did its levels correlate with the degree of hypoxia in the blood (data not
shown). Previous studies have variably reported placental
expression of VEGF to increase [27, 36], decrease, or not
change in IUGR [37, 38]. It has been suggested that placental
insufficiency can result in hyperoxia localized to the placental
villi [39, 40] which may limit or decrease VEGF expression
from the villous trophoblast layer [41–43]. Whether placental
growth factor (PlGF), which is increased in circulation in well
oxygenated conditions of pregnancies, upregulates PAI-1 is
unknown, though it may plausibly do so through vascular
endothelial growth factor receptor 1 (FLT-1) binding [44].
PAI-1, like VEGF, is also directly upregulated via HIF1 in hypoxia [30], and PAI-1 levels did increase very significantly in correlation with decreasing venous oxygen levels
(Figure 2(b) (iii)) in placental insufficiency pregnancies. This
association with oxygen and the lack of association with
regulatory cytokines in placental insufficiency suggests that

the large increase in PAI-1 levels observed may be through
direct HIF-1 mediated transcription. Similarly the lack of
strong association with corticosteroids suggests that although
corticosteroid administration to assist in lung maturation
in severely preterm birth pregnancies may have some effect
on fetal-placental PAI-1 expression, there was no significant
difference observed in our cohort. Furthermore, the changes
were not of a magnitude that would suggest they would
mask the 10-fold mean change observed in placental insufficiency. Nevertheless, investigations of the expression of PAI1 should account for cortisone administration as a potential
confounder to a marker in severe preterm pregnancies.
PAI-1 proangiogenic action has been suggested to be
through modifying the balance of plasmin degradation of the
ECM providing a stable ECM platform for cell migration,
proliferation, and vessel maturation [45]. It additionally has
a vitronectin binding function that may block the binding
of endothelial integrins in cell migration [46]. Mice lacking
PAI-1 expression stave off invasion and vascularization of
transplanted malignant tumors [8]. It is required for postischemic injury angiogenesis in the retina in a murine model
of angiogenesis [7]. Recent studies have found that PAI-1
knockout mice have transiently reduced maternal and fetalplacental vasculature [47].
The range of PAI-1 spanned ∼1–50 ng/mL in normal pregnancy, typically <10 ng/mL. With hypoxic placental insufficiency it was ∼50 ng/mL on average and ranged 3x higher
(Figure 1(a)). In line with this, the best cut-off separation
determined from the ROC was at 43.3 ng/mL. In context,
circulating PAI-1 levels ranging from 50 ng/mL or higher
represent a significant departure from normal physiological
levels which may influence function. Indeed PAI-1 levels
were strongly associated with angiogenesis (Figure 5(b) (ii)),
and its inhibition was sufficient to largely reverse plasmainduced angiogenesis in vitro (Figure 6). The effects of a neartotal inhibition of PAI-1 are not dissimilar to some control
pregnancies which were <1 𝜇g/mL. Circulating concentrations of >30 ng/mL have significant physiological effect to
nearly triple the risk of breast cancer mortality by comparison
[48]. PAI-1 is strongly associated with tumor vascularization,
where its increased levels have been associated with poor
prognosis [9, 10, 13]. Late gestation fetal-placental vascular conditions in placental insufficiency are analogous to
conditions in some breast tumors in that there is vascular
dysregulation, inflammation, hypoxia, and altered regulation
of VEGF and other genes via HIF-1 [49].
IUGR has multiple etiology, and the stringency in excluding nonidiopathic placental insufficiency and other complications of our patient selection (detailed in Section 2) is a critical strength of this study. Studied samples represent the most
severe cases of IUGR, with very low birth weight percentile,
and were critically verified to have significantly elevated
resistance index for gestational age to only include confirmed
vascular malformations that are hallmark of placental insufficiency (Table 1) [50, 51]. Although most controls did not have
Doppler assessment of placental insufficiency, the lack of any
indication of IUGR as determined by routine ultrasound and
regular symphysis fundal height examination and confirmed
by birth weight percentile assessment rules out the possibility
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Figure 4: Umbilical artery plasma from PI pregnancies has increased angiogenic potency. Angiogenic tube formation assay of HUVECs
plated onto extracellular matrix protein gel in the presence of 1% venous umbilical cord plasma from PI and control. Assays were individually
performed on PI (𝑛 = 10) and control (𝑛 = 10) samples in duplicate experiments. Each sample was gestational age matched within 5 days.
(a) Representative fields are shown from serum-free control (SF), control pregnancy plasma, and PI plasma. (b) Quantification was using the
standard method of calculating total tube length of all cord formation, and the total number of branches per field. Results were determined
by averaging across four fields per well, with triplicate wells per experiment (one-way ANOVA, ∗∗ 𝑝 < 0.01, and ∗∗∗ 𝑝 < 0.001). Standard
error of the mean is indicated.

of an abnormal Doppler finding in controls, as indeed these
tests were not medically indicated for these patients. For this
reason it was possible to determine ROC confidently against
a “gold standard.” This was not only helpful in isolating a
type case where the greatest changes might be expected but
also reduced the likelihood of inclusion of normal percentile
cases due inaccuracies in estimated gestational ages. Controls
were selected based on gestational age matching for the
overall effect of a very well controlled study group of severe
idiopathic IUGR with placental insufficiency. However the
molecular effects of an enrichment of spontaneous preterm
birth subjects in controls versus indicated preterm birth in
placental insufficiency must be considered. A review of the
literature offers no conclusive links of changing plasma PAI1 levels to initiation of parturition, though it is involved in
proteolytic events in the decidua.
Conversely, the stringent exclusion criteria may possibly
have directed collection efforts towards the most evident
placental insufficiency cases that may potentially be more
severe than average that could affect the true predictive value
of PAI-1. Placental insufficiency is among the most severe

of the etiologies, a comparison between large cohorts of
mixed etiologies would best determine its predictive value.
Nevertheless PAI-1’s 10-fold mean separation from control
and strong correlations with pathological factors like hypoxia
are strong indications of its potential specificity. Finally, our
measurements of PAI-1 were necessarily postnatal. Since the
genesis of the pathology may initiate largely between 7 and 25
weeks [52], our experiments are likely capturing the effects
but not causes of a restricted and reduced vasculature. To
what extent the severe changes in PAI-1 initiate the pathology
is therefore left unassessed.
For tumor development, it has been demonstrated that
elevated circulating PAI-1 has significant implications as a
biomarker even within the normal physiological range. Its
predictive value has been tied to its function as a central
angiogenic mediator. Here we have discovered circulating
PAI-1 levels in venous cord blood as highly elevated and
strongly associated with the hypoxemia borne of the vascular pathology of placental insufficiency. The levels correlated directly to the plasma’s increased angiogenic potency.
Although, in metabolic substrate restrictive conditions,
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Figure 5: Angiogenic potency correlates to PAI-1 levels in PI. The angiogenic potency of the plasma that was measured (Figure 4) was
correlated to PAI-1 and VEGF. (a) In control pregnancies, the angiogenic potency was strongly dependent on total VEGF levels (i) in both
measurements of tube formation and branching (𝑟 = 0.71 and 0.74, 𝑝 < 0.05, resp.). However there was no relationship to PAI-1 (ii). (b)
Conversely in pregnancies with PI, measure of angiogenesis was unrelated to VEGF levels (i) and, instead, correlated to circulating PAI-1
levels (ii) for both tube formation and branching (𝑟 = 0.65 and 0.67, 𝑝 < 0.01 and <0.05, resp.) (open: control, closed: PI).
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Figure 6: PAI-1 neutralization results in angiogenic suppression. HUVEC angiogenic tube formation assay on extracellular matrix in the
presence of 1% venous umbilical cord plasma from PI pregnancies. PAI-1 neutralizing antibody was added in indicated amounts (𝜇g/mL) as
well as plasma-free, and anti-GAPDH antibody negative controls and the total tube length and branching quantified following incubations. (a)
Representative 100x magnified fields are shown. (b) Significant differences from the plasma + treatment were determined by one-way ANOVA.
PAI-1 inhibition attenuated angiogenic simulation measured by both total tube length and branching. (c) Experiments were repeated with
six fetal umbilical cord plasma samples from pregnancies with PI, using 1 𝜇g/mL of PAI-1 inhibiting antibody. Standard error of the mean is
indicated (one-way ANOVA) (∗∗ 𝑝 < 0.01 and ∗∗∗ 𝑝 < 0.001).
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circulating protein levels changes may be adaptive [53–55],
it is speculated that PAI-1 may be contributing to the vascular
pathology in placental insufficiency by promoting vascular
resistance. In summary, our findings identify PAI-1’s potential
utility as a postnatal marker of placental disease. Its clinical
use may supplement existing blood gas measurements that
are rather more indicative of acute acidosis than placental
function per se.

5. Conclusions
PAI-1 is predictive of placental dysfunction in placental
insufficiency. Its levels are strongly related to hypoxia where
it may be upregulated directly through HIF-1 mediated
mechanisms. Increased plasma PAI-1 levels contribute to
upregulated angiogenic mechanisms. A large prospective
cohort comparing PAI-1 levels together with the findings of
umbilical artery Doppler would determine its utility in retrospectively identifying patients born following a pregnancy
with placental dysfunction for etiological classification in
IUGR.
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